Response-driven dosing with AUSTEDO1

Dial representing dosing up to 48 mg/day. In clinical trials, the average daily dose was >36 mg.

Please see additional dosing and administration information at the bottom of this page.

Increase dose until symptom control is effectively and tolerably achieved1

Start treatment at 12 mg/day

Blue arrow pointing right Blue arrow pointing right

Increase by 6 mg/day weekly1

12 mg
/day

(6 mg BID)

SD

6

SD

6

Week 1

[14 tablets
per 7 days]

18 mg
/day

(9 mg BID)

SD

9

SD

9

Week 2

[14 tablets
per 7 days]

24 mg/
day

(12 mg BID)

SD

12

SD

12

Week 3

[14 tablets
per 7 days]

30 mg/
day

(15 mg BID)

SD

6

SD

6

SD

9

SD

9

Week 4

[28 tablets
per 7 days]

36 mg/
day

(18 mg BID)

SD

9

SD

9

SD

9

SD

9

Week 5

[28 tablets
per 7 days]

Average dose in trials

was >36 mg/day1,2

42 mg/
day

(21 mg BID)

SD

9

SD

9

SD

12

SD

12

Week 6

[28 tablets
per 7 days]

48 mg/
day

(24 mg BID)

SD

12

SD

12

SD

12

SD

12

Week 7

[28 tablets
per 7 days]

AUSTEDO is available in 6-mg, 9-mg, and 12-mg tablets1

6 mg AUSTEDO®  (deutetrabenazine) tablet.9 mg AUSTEDO®  (deutetrabenazine) tablet. 12 mg AUSTEDO®  (deutetrabenazine) tablet.

Tablets not shown at actual size.

Additional dosing and administration information1

  • Administer total daily dosages in 2 divided doses
  • AUSTEDO should be taken with food
  • AUSTEDO® (deutetrabenazine) tablets should be swallowed whole. Tablets should not be chewed, crushed, or broken

Watch TD Movements Over Time

See Charlene’s treatment journey—find information on titration and the effects on symptom control.

See Charlene’s treatment journey—find information on titration and the effects on symptom control.

TD, tardive dyskinesia.

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022;13:773999. doi:10.3389/fneur.2022.773999